Recent advances in antibody-drug conjugates

Area of Science:

• Biotechnology
• Pharmacology
• Oncology

Background:

• Antibody-drug conjugates (ADCs) integrate antibody targeting with potent small-molecule drugs.
• Recent advancements in antibody engineering, bioconjugation, linker design, and payload development have led to significant clinical success and FDA approvals for ADCs.
• The therapeutic landscape for ADCs has evolved rapidly, demonstrating increasing efficacy and broader applicability.

Purpose of the Study:

• To highlight key innovations driving the next generation of ADCs.
• To focus on site-selective conjugation, advanced linker technologies for higher drug-to-antibody ratios (DARs), and novel payload classes.
• To discuss the expanding therapeutic scope of ADCs beyond oncology and identify future challenges.

Main Methods:

• Review and synthesis of recent innovations in ADC technology.
• Focus on site-selective conjugation strategies for improved ADC homogeneity.
• Analysis of linker technologies enabling higher drug-to-antibody ratios (DARs).
• Exploration of emerging payload classes with novel mechanisms of action.

Main Results:

• Site-selective conjugation enables more precise control over ADC structure and function.
• Advanced linker technologies facilitate higher drug-to-antibody ratios (DARs), potentially enhancing potency.
• Emerging payload classes offer novel mechanisms of action, expanding therapeutic options.
• ADCs are demonstrating potential in therapeutic areas beyond oncology.

Conclusions:

• Innovations in conjugation, linkers, and payloads are defining the next generation of ADCs.
• Higher drug-to-antibody ratios (DARs) and novel payloads are key areas of advancement.
• The expanding applications of ADCs beyond oncology signal a promising future, contingent on addressing key challenges.